Florida Hospital Cancer Institute

Summary

Florida Hospital Cancer Institute is a medical facility located in Orlando, Florida. This center is recognized for care of Lung Cancer, Leukemia, Ovarian Cancer, Breast Cancer, Pancreatic Cancer and other specialties. Florida Hospital Cancer Institute is involved with conducting 215 clinical trials across 231 conditions. There are 8 research doctors associated with this hospital, such as Carlos Alemany, Mohamedtaki A. Tejani, Guru P Sonpavde, MD, and Robert Holloway, MD.

Top PIs

Clinical Trials running at Florida Hospital Cancer Institute

Ovarian Cancer

Lung Cancer

Pancreatic Cancer

Cancer

Solid Tumors

Endometrial Cancer

Breast Cancer

Breast cancer

Small Cell Lung Cancer

Gastric Cancer

Trastuzumab Deruxtecan + Bevacizumab

for Ovarian Cancer

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Recruiting

2 awards

Phase 3

5 criteria

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Recruiting

2 awards

Phase 3

7 criteria

NKT3964

for Solid Tumors

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDEs based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).

Recruiting

1 award

Phase 1

9 criteria